MedTrace Logo

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

NCT02720536 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2020-03-03

Study results available
· View outcomes & findings →

Summary

Extend evaluation of deferasirox film-coated tablet (FCT) formulation

Conditions

  • Chronic Iron Overload

Interventions

DRUG

Deferasirox

Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-16
Primary Completion
2019-07-23
Completion
2019-07-23

Countries

  • Austria
  • Greece
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02720536 on ClinicalTrials.gov